Naresh Kumar
Director Bioscience Immunology AstraZeneca
Seminars
Thursday 29th October 2026
Advancing CD8-Biased T-Cell Engagers to Enhance Precision Immune Modulation & Improve Safety in Autoimmune Disease
11:00 am
- Developing next-generation CD8-biased T-cell engager platforms targeting B cells, plasma cells, and broader immune biology to achieve potent and selective immunecell depletion while minimizing excessive immune activation
- Evaluating how CD8-biased engagement strategies may reduce cytokine release and lower cytokine release syndrome risk while retaining strong in vitro potency, leveraging translational data generated from cytokine release assays, healthy donor studies, and patient-derived immune-cell samples
- Presenting emerging insights from AstraZeneca’s externally disclosed autoimmune T-cell engager programs, including the CD20-targeting molecule “5492,” to demonstrate how precision immune modulation and differentiated safety profiles may support competitive positioning within an increasingly crowded therapeutic landscape
